Antibody-drug conjugates (ADCs) are a promising targeted cancer therapy; however, patient
selection based solely on target antigen expression without consideration for cytotoxic …

Purpose: A subset of primary prostate cancer expresses programmed death-ligand 1 (PD-L1),
but whether they have a unique tumor immune microenvironment or genomic features is …

Purpose: Therapies targeting the androgen receptor (AR) have improved the outcome for
patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively …

Purpose: Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and a
model of targeted molecular therapy. GIST depends on oncogenic KIT signaling and …

Advanced prostate malignancies are a leading cause of cancer-related deaths in men, in
large part due to our incomplete understanding of cellular drivers of disease progression. We …

We have established highly clinically relevant PDXs of ADT-induced dormant prostate cancer
and identified two dormancy subtypes, leading to the development of a novel predicative …

Purpose: The impact of androgen receptor (AR) activity in breast cancer biology is unclear.
We characterized and tested a novel therapy to an AR-governed target in breast cancer. …

Intratumoral heterogeneity is a well-documented feature of human cancers and is associated
with outcome and treatment resistance. However, a heterogeneous tumor transcriptome …

Targeting the androgen receptor (AR) pathway prolongs survival in patients with prostate
cancer, but resistance rapidly develops. Understanding this resistance is confounded by a lack …

To resist lineage-dependent therapies such as androgen receptor inhibition, prostate luminal
epithelial adenocarcinoma cells often adopt a stem-like state resulting in lineage plasticity …